Do analysts recommend BCTX or OBSV?

Given ObsEva's higher possible upside, analysts plainly believe ObsEva is more favorable than Briacell Therap. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Briacell Therap 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 ObsEva 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has preferable valuation and earnings, BCTX or OBSV?

Briacell Therap is trading at a lower price-to-earnings ratio than ObsEva, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Briacell Therap N/A N/A -$26.31M -$7.92 N/A ObsEva N/A N/A -$58.38M -$0.92 N/A

Is BCTX or OBSV more profitable?

Briacell Therap's return on equity of -153.53% beat ObsEva's return on equity. Company Net Margins Return on Equity Return on Assets Briacell Therap N/A -153.53% -129.26% ObsEva N/A -416.36% -92.01%

Do analysts recommend ABVC or OBSV?

Given ObsEva's higher possible upside, analysts plainly believe ObsEva is more favorable than ABVC BioPharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ABVC BioPharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 ObsEva 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has stronger valuation and earnings, ABVC or OBSV?

ABVC BioPharma is trading at a lower price-to-earnings ratio than ObsEva, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ABVC BioPharma N/A N/A -$7.91M -$0.40 N/A ObsEva N/A N/A -$58.38M -$0.92 N/A

Is ABVC or OBSV more profitable?

ABVC BioPharma's return on equity of -62.46% beat ObsEva's return on equity. Company Net Margins Return on Equity Return on Assets ABVC BioPharma N/A -62.46% -39.99% ObsEva N/A -416.36% -92.01%

Does the media prefer ABVC or OBSV?

In the previous week, ABVC BioPharma had 1 more articles in the media than ObsEva. MarketBeat recorded 2 mentions for ABVC BioPharma and 1 mentions for ObsEva. ABVC BioPharma's average media sentiment score of 0.93 beat ObsEva's score of 0.00 indicating that ABVC BioPharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ABVC BioPharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ObsEva 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend PLRZ or OBSV?

Given ObsEva's higher possible upside, analysts clearly believe ObsEva is more favorable than Polyrizon. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Polyrizon 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 ObsEva 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has higher earnings & valuation, PLRZ or OBSV?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Polyrizon N/A N/A -$3.34M N/A N/A ObsEva N/A N/A -$58.38M -$0.92 N/A

Is PLRZ or OBSV more profitable?

Polyrizon's return on equity of 0.00% beat ObsEva's return on equity. Company Net Margins Return on Equity Return on Assets Polyrizon N/A N/A N/A ObsEva N/A -416.36% -92.01%

Does the media favor PLRZ or OBSV?

In the previous week, Polyrizon had 1 more articles in the media than ObsEva. MarketBeat recorded 2 mentions for Polyrizon and 1 mentions for ObsEva. Polyrizon's average media sentiment score of 1.32 beat ObsEva's score of 0.00 indicating that Polyrizon is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Polyrizon 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ObsEva 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate OBSV or VYNE?

Given ObsEva's higher probable upside, equities research analysts clearly believe ObsEva is more favorable than VYNE Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ObsEva 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 VYNE Therapeutics 1 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.75

Is OBSV or VYNE more profitable?

ObsEva has a net margin of 0.00% compared to VYNE Therapeutics' net margin of -4,726.21%. VYNE Therapeutics' return on equity of -70.42% beat ObsEva's return on equity. Company Net Margins Return on Equity Return on Assets ObsEva N/A -416.36% -92.01% VYNE Therapeutics -4,726.21% -70.42% -63.46%

Does the media refer more to OBSV or VYNE?

In the previous week, VYNE Therapeutics had 6 more articles in the media than ObsEva. MarketBeat recorded 7 mentions for VYNE Therapeutics and 1 mentions for ObsEva. VYNE Therapeutics' average media sentiment score of 0.05 beat ObsEva's score of 0.00 indicating that VYNE Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ObsEva 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral VYNE Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is ALGS or OBSV more profitable?

ObsEva has a net margin of 0.00% compared to Aligos Therapeutics' net margin of -1,919.68%. Aligos Therapeutics' return on equity of -139.47% beat ObsEva's return on equity. Company Net Margins Return on Equity Return on Assets Aligos Therapeutics -1,919.68% -139.47% -90.88% ObsEva N/A -416.36% -92.01%

ObsEva (OBSV) Competitors

Compare

OBSV vs. BCTX, ABVC, PLRZ, VYNE, and ALGS

Should you buy ObsEva stock or one of its competitors? MarketBeat compares ObsEva with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with ObsEva include Briacell Therap (BCTX), ABVC BioPharma (ABVC), Polyrizon (PLRZ), VYNE Therapeutics (VYNE), and Aligos Therapeutics (ALGS). These companies are all part of the "pharmaceutical products" industry.

How does ObsEva compare to Briacell Therap?

Briacell Therap (NASDAQ:BCTX) and ObsEva (NASDAQ:OBSV) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, dividends, valuation, institutional ownership and media sentiment.

15.4% of Briacell Therap shares are held by institutional investors. Comparatively, 17.5% of ObsEva shares are held by institutional investors. 0.7% of Briacell Therap shares are held by company insiders. Comparatively, 14.4% of ObsEva shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Given ObsEva's higher possible upside, analysts plainly believe ObsEva is more favorable than Briacell Therap.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Briacell Therap	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
ObsEva	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Briacell Therap's return on equity of -153.53% beat ObsEva's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Briacell Therap	N/A	-153.53%	-129.26%
ObsEva	N/A	-416.36%	-92.01%

In the previous week, Briacell Therap and Briacell Therap both had 1 articles in the media. Briacell Therap's average media sentiment score of 1.89 beat ObsEva's score of 0.00 indicating that Briacell Therap is being referred to more favorably in the media.

Company	Overall Sentiment
Briacell Therap	Very Positive
ObsEva	Neutral

Briacell Therap is trading at a lower price-to-earnings ratio than ObsEva, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Briacell Therap	N/A	N/A	-$26.31M	-$7.92	N/A
ObsEva	N/A	N/A	-$58.38M	-$0.92	N/A

Briacell Therap has a beta of 1.15, indicating that its stock price is 15% more volatile than the broader market. Comparatively, ObsEva has a beta of 0.68, indicating that its stock price is 32% less volatile than the broader market.

Summary

ObsEva beats Briacell Therap on 6 of the 11 factors compared between the two stocks.

How does ObsEva compare to ABVC BioPharma?

ABVC BioPharma (NASDAQ:ABVC) and ObsEva (NASDAQ:OBSV) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, dividends, profitability, media sentiment, valuation, institutional ownership, analyst recommendations and earnings.

ABVC BioPharma's return on equity of -62.46% beat ObsEva's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ABVC BioPharma	N/A	-62.46%	-39.99%
ObsEva	N/A	-416.36%	-92.01%

ABVC BioPharma has a beta of 0.54, indicating that its stock price is 46% less volatile than the broader market. Comparatively, ObsEva has a beta of 0.68, indicating that its stock price is 32% less volatile than the broader market.

11.4% of ABVC BioPharma shares are owned by institutional investors. Comparatively, 17.5% of ObsEva shares are owned by institutional investors. 19.0% of ABVC BioPharma shares are owned by company insiders. Comparatively, 14.4% of ObsEva shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Given ObsEva's higher possible upside, analysts plainly believe ObsEva is more favorable than ABVC BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ABVC BioPharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
ObsEva	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

ABVC BioPharma is trading at a lower price-to-earnings ratio than ObsEva, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ABVC BioPharma	N/A	N/A	-$7.91M	-$0.40	N/A
ObsEva	N/A	N/A	-$58.38M	-$0.92	N/A

In the previous week, ABVC BioPharma had 1 more articles in the media than ObsEva. MarketBeat recorded 2 mentions for ABVC BioPharma and 1 mentions for ObsEva. ABVC BioPharma's average media sentiment score of 0.93 beat ObsEva's score of 0.00 indicating that ABVC BioPharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ABVC BioPharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ObsEva	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

ABVC BioPharma beats ObsEva on 8 of the 12 factors compared between the two stocks.

How does ObsEva compare to Polyrizon?

Polyrizon (NASDAQ:PLRZ) and ObsEva (NASDAQ:OBSV) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, analyst recommendations, media sentiment, dividends, earnings and risk.

In the previous week, Polyrizon had 1 more articles in the media than ObsEva. MarketBeat recorded 2 mentions for Polyrizon and 1 mentions for ObsEva. Polyrizon's average media sentiment score of 1.32 beat ObsEva's score of 0.00 indicating that Polyrizon is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Polyrizon	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ObsEva	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Polyrizon's return on equity of 0.00% beat ObsEva's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Polyrizon	N/A	N/A	N/A
ObsEva	N/A	-416.36%	-92.01%

Given ObsEva's higher possible upside, analysts clearly believe ObsEva is more favorable than Polyrizon.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Polyrizon	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
ObsEva	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

17.5% of ObsEva shares are owned by institutional investors. 14.4% of ObsEva shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Polyrizon	N/A	N/A	-$3.34M	N/A	N/A
ObsEva	N/A	N/A	-$58.38M	-$0.92	N/A

Polyrizon has a beta of -1.59, indicating that its share price is 259% less volatile than the broader market. Comparatively, ObsEva has a beta of 0.68, indicating that its share price is 32% less volatile than the broader market.

Summary

Polyrizon beats ObsEva on 6 of the 10 factors compared between the two stocks.

How does ObsEva compare to VYNE Therapeutics?

ObsEva (NASDAQ:OBSV) and VYNE Therapeutics (NASDAQ:VYNE) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, risk, earnings, institutional ownership, media sentiment, analyst recommendations, profitability and dividends.

Given ObsEva's higher probable upside, equities research analysts clearly believe ObsEva is more favorable than VYNE Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ObsEva	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
VYNE Therapeutics	1 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.75

VYNE Therapeutics has higher revenue and earnings than ObsEva. VYNE Therapeutics is trading at a lower price-to-earnings ratio than ObsEva, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ObsEva	N/A	N/A	-$58.38M	-$0.92	N/A
VYNE Therapeutics	$454K	37.43	-$26.48M	-$0.38	N/A

ObsEva has a beta of 0.68, indicating that its share price is 32% less volatile than the broader market. Comparatively, VYNE Therapeutics has a beta of 2, indicating that its share price is 100% more volatile than the broader market.

17.5% of ObsEva shares are held by institutional investors. Comparatively, 83.8% of VYNE Therapeutics shares are held by institutional investors. 14.4% of ObsEva shares are held by insiders. Comparatively, 3.0% of VYNE Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, VYNE Therapeutics had 6 more articles in the media than ObsEva. MarketBeat recorded 7 mentions for VYNE Therapeutics and 1 mentions for ObsEva. VYNE Therapeutics' average media sentiment score of 0.05 beat ObsEva's score of 0.00 indicating that VYNE Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ObsEva	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
VYNE Therapeutics	0 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

ObsEva has a net margin of 0.00% compared to VYNE Therapeutics' net margin of -4,726.21%. VYNE Therapeutics' return on equity of -70.42% beat ObsEva's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ObsEva	N/A	-416.36%	-92.01%
VYNE Therapeutics	-4,726.21%	-70.42%	-63.46%

Summary

VYNE Therapeutics beats ObsEva on 10 of the 14 factors compared between the two stocks.

How does ObsEva compare to Aligos Therapeutics?

Aligos Therapeutics (NASDAQ:ALGS) and ObsEva (NASDAQ:OBSV) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, analyst recommendations, risk, media sentiment, earnings and dividends.

Aligos Therapeutics has a beta of 2.26, suggesting that its stock price is 126% more volatile than the broader market. Comparatively, ObsEva has a beta of 0.68, suggesting that its stock price is 32% less volatile than the broader market.

60.4% of Aligos Therapeutics shares are held by institutional investors. Comparatively, 17.5% of ObsEva shares are held by institutional investors. 7.8% of Aligos Therapeutics shares are held by company insiders. Comparatively, 14.4% of ObsEva shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Aligos Therapeutics and Aligos Therapeutics both had 1 articles in the media. Aligos Therapeutics' average media sentiment score of 1.87 beat ObsEva's score of 0.00 indicating that Aligos Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Aligos Therapeutics	Very Positive
ObsEva	Neutral

ObsEva has a net margin of 0.00% compared to Aligos Therapeutics' net margin of -1,919.68%. Aligos Therapeutics' return on equity of -139.47% beat ObsEva's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aligos Therapeutics	-1,919.68%	-139.47%	-90.88%
ObsEva	N/A	-416.36%	-92.01%

Aligos Therapeutics currently has a consensus price target of $38.50, suggesting a potential upside of 843.63%. Given Aligos Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Aligos Therapeutics is more favorable than ObsEva.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aligos Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
ObsEva	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Aligos Therapeutics has higher revenue and earnings than ObsEva. Aligos Therapeutics is trading at a lower price-to-earnings ratio than ObsEva, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aligos Therapeutics	$4.71M	5.37	-$24.19M	-$8.69	N/A
ObsEva	N/A	N/A	-$58.38M	-$0.92	N/A

Summary

Aligos Therapeutics beats ObsEva on 11 of the 15 factors compared between the two stocks.

Get ObsEva News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OBSV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

OBSV vs. The Competition

Export

Metric	ObsEva	Pharmaceutical Industry	Medical Sector	NASDAQ Exchange
Market Cap	$7.94M	$975.11M	$6.87B	$12.26B
Dividend Yield	N/A	4.84%	2.67%	9.79%
P/E Ratio	0.00	1.53	27.14	23.64
Price / Sales	N/A	105.75	517.06	88.99
Price / Cash	N/A	20.06	50.54	59.64
Price / Book	N/A	8.47	10.28	6.07
Net Income	-$58.38M	-$2.70M	$3.60B	$331.99M

ObsEva Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
OBSV ObsEva	N/A	N/A	N/A	N/A	$7.94M	N/A	N/A	50
BCTX Briacell Therap	0.6757 of 5 stars	$3.56 -1.0%	N/A	-55.7%	$30.96M	N/A	N/A	8	Positive News
ABVC ABVC BioPharma	0.5097 of 5 stars	$1.16 -1.7%	N/A	-64.6%	$30.16M	$510K	N/A	30	Positive News
PLRZ Polyrizon	0.4575 of 5 stars	$14.40 +0.1%	N/A	+76.0%	$29.95M	N/A	N/A	N/A	Positive News Gap Down
VYNE VYNE Therapeutics	1.0205 of 5 stars	$0.89 -1.1%	N/A	-62.0%	$29.64M	$570K	N/A	30	News Coverage Short Interest Increase Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:OBSV) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ObsEva (OBSV) Competitors

OBSV vs. BCTX, ABVC, PLRZ, VYNE, and ALGS

How does ObsEva compare to Briacell Therap?

Summary

How does ObsEva compare to ABVC BioPharma?

Summary

How does ObsEva compare to Polyrizon?

Summary

How does ObsEva compare to VYNE Therapeutics?

Summary

How does ObsEva compare to Aligos Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OBSV vs. The Competition

ObsEva Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ObsEva (OBSV) Competitors

OBSV vs. BCTX, ABVC, PLRZ, VYNE, and ALGS

How does ObsEva compare to Briacell Therap?

Do institutionals and insiders have more ownership in BCTX or OBSV?

Do analysts recommend BCTX or OBSV?

Is BCTX or OBSV more profitable?

Does the media prefer BCTX or OBSV?

Which has preferable valuation and earnings, BCTX or OBSV?

Which has more volatility and risk, BCTX or OBSV?

Summary

How does ObsEva compare to ABVC BioPharma?

Is ABVC or OBSV more profitable?

Which has more volatility & risk, ABVC or OBSV?

Do insiders & institutionals hold more shares of ABVC or OBSV?

Do analysts recommend ABVC or OBSV?

Which has stronger valuation and earnings, ABVC or OBSV?

Does the media prefer ABVC or OBSV?

Summary

How does ObsEva compare to Polyrizon?

Does the media favor PLRZ or OBSV?

Is PLRZ or OBSV more profitable?

Do analysts recommend PLRZ or OBSV?

Do institutionals and insiders hold more shares of PLRZ or OBSV?

Which has higher earnings & valuation, PLRZ or OBSV?

Which has more risk and volatility, PLRZ or OBSV?

Summary

How does ObsEva compare to VYNE Therapeutics?

Do analysts rate OBSV or VYNE?

Which has stronger valuation and earnings, OBSV or VYNE?

Which has more risk and volatility, OBSV or VYNE?

Do insiders and institutionals believe in OBSV or VYNE?

Does the media refer more to OBSV or VYNE?

Is OBSV or VYNE more profitable?

Summary

How does ObsEva compare to Aligos Therapeutics?

Which has more volatility & risk, ALGS or OBSV?

Do insiders & institutionals hold more shares of ALGS or OBSV?

Does the media favor ALGS or OBSV?

Is ALGS or OBSV more profitable?

Do analysts prefer ALGS or OBSV?

Which has stronger earnings and valuation, ALGS or OBSV?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OBSV vs. The Competition

ObsEva Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools